希罗达对食道癌放射治疗增敏的临床研究  

Reinforcement Effect of Xeloda for Radiotherapy of Esophagus Cancer

作　　者：邹雨荷[1] 毛汉[1] 谭丽蓉[1] 李凯新[1] 丁小凡[1] 

机构地区：[1]广东省江门市中心医院肿瘤科,529070

出　　处：《医学理论与实践》2007年第8期879-881,共3页The Journal of Medical Theory and Practice

基　　金：江门市科技攻关项目

摘　　要：目的：探讨希罗达配合放疗对食道癌的临床疗效和毒副反应。方法：选取40例食道癌患者，随机分为2组，各20例，试验组进行放射治疗＋希罗达联合治疗；放疗方法两组均用直线加速器6MV-X线三野治疗，5次／周，2Gy／次，区域总剂量60-66Gy／30-33次／6～7周，同步给予希罗达500mg／m^2，2次／d，对照组单纯放射治疗。结果：全程治疗后2个月，两组食道病灶及区域淋巴结消退率（CR＋PR）分别为60％（12／20）、25％（5／20），差异有显著性（P〈0．05）；吞咽困难的改善优于对照组（P〈0．05）；毒副反应与对照组相当（P〉0．05）均较轻，未见Ⅲ、Ⅳ级毒副反应。结论：希罗达作为食道癌患者的放疗增敏剂有较好的临床放疗增敏作用，其毒副反应患者可耐受。Objective： To investigate the curative effect and toxicity of xeloda combined with radiation therapy on patients with esophagus carcinoma. Methods： 40 patients were randomly divided into two groups： RT plus xeloda （RT＋X） group and radiotherapy （RT） group. The RT＋X group （20 cases） was given xeloda 500mg/m^2, twice per day, in the course of RT. The RT （conventional RT ） was carried out by linear accelerator （6MV-Xray） to irradiate the e- sophagus cancer to 60-66Gy/30-33F/6-7W in both groups. Results：The local control rates 2 months after therapy terminated were 60% in RT＋X group and 25% in RT group（P〈0. 05） ; The swallowing difficulties and the pains of the chest in RT＋X group realized improvement. Toxicity in two groups were well tolerated in majority of patients. Conclusion： Xeloda is effective in increasing tumor radiation sensitivity for the patients with esophagus carcinoma and the toxicity is well-tolerated.

关 键 词：食道肿瘤 放射增敏 放射治疗 希罗达 

分 类 号：R735.1[医药卫生—肿瘤]